Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 16.33% is 15% below its 5-year average of 19.11%, around the middle of its 5-year range (10.76%–27.14%).
As of the fiscal period ended Tuesday, June 30, 2026. 9.55% below its 12-month average of 18.06%.
Reported quarterly EBITDA margin; no daily interpolation.
EBITDA MARGIN
16.33%
EBITDA MARGIN AVG TTM
18.06%
EBITDA MARGIN AVG 3Y
18.38%
EBITDA MARGIN AVG 5Y
19.11%
EBITDA MARGIN AVG 10Y
18.96%
EBITDA MARGIN AVG 15Y
18.90%
EBITDA MARGIN AVG 20Y
19.49%
CURRENT VS TTM AVG
-9.55%
CURRENT VS 3Y AVG
-11.14%
CURRENT VS 5Y AVG
-14.54%
CURRENT VS 10Y AVG
-13.86%
CURRENT VS 15Y AVG
-13.59%
CURRENT VS 20Y AVG
-16.21%
Quest Diagnostics Incorporated
Market Cap
$26.21B
EBITDA Margin
16.33%
TTM Avg
18.06%
3Y Avg
18.38%
5Y Avg
19.11%
Market Cap
$26.46B
EBITDA Margin
15.75%
TTM Avg
14.53%
3Y Avg
14.10%
5Y Avg
17.90%
Market Cap
$24.72B
EBITDA Margin
24.13%
TTM Avg
25.03%
3Y Avg
27.36%
5Y Avg
27.53%
Market Cap
$24.54B
EBITDA Margin
27.93%
TTM Avg
16.21%
3Y Avg
17.95%
5Y Avg
14.24%
Market Cap
$24.03B
EBITDA Margin
-147.07%
TTM Avg
-132.24%
3Y Avg
-66.39%
5Y Avg
-46.73%
Market Cap
$29.02B
EBITDA Margin
30.90%
TTM Avg
31.59%
3Y Avg
31.63%
5Y Avg
30.80%
Market Cap
$29.60B
EBITDA Margin
15.00%
TTM Avg
4.83%
3Y Avg
-18.55%
5Y Avg
-52.26%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated (DGX) | $26.21B | 16.33% | 18.06% | 18.38% | 19.11% |
| Labcorp Holdings Inc. (LH)vs › | $26.46B | 15.75% | 14.53% | 14.10% | 17.90% |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.72B | 24.13% | 25.03% | 27.36% | 27.53% |
| Incyte Corporation (INCY)vs › | $24.54B | 27.93% | 16.21% | 17.95% | 14.24% |
| Moderna, Inc. (MRNA)vs › | $24.03B | -147.07% | -132.24% | -66.39% | -46.73% |
| Mettler-Toledo International Inc. (MTD)vs › | $29.02B | 30.90% | 31.59% | 31.63% | 30.80% |
| BioNTech SE (BNTX)vs › | $23.31B | -9.29% | -23.11% | 12.60% | 20.38% |
| STERIS plc (STE)vs › | $23.22B | 26.76% | 25.68% | 26.35% | 25.75% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $29.60B | 15.00% | 4.83% | -18.55% | -52.26% |
| Medline Inc. (MDLN)vs › | $29.63B | 10.26% | 11.41% | 10.38% | 10.38% |
Gross Margin
33.1%
EBITDA Margin
16.3%
Operating Margin
14.1%
Net Margin
9.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 16.33% |
| 2026-03-31 | 15.06% |
| 2025-12-31 | 19.10% |
| 2025-09-30 | 18.75% |
| 2025-06-30 | 21.04% |
| 2025-03-31 | 18.33% |
| 2024-12-31 | 18.92% |
| 2024-09-30 | 18.29% |
| 2024-06-30 | 19.69% |
| 2024-03-31 | 17.58% |
| 2023-12-31 | 16.43% |
| 2023-09-30 | 19.74% |
| 2023-06-30 | 19.67% |
| 2023-03-31 | 17.67% |
| 2022-12-31 | 10.76% |
| 2022-09-30 | 20.11% |
| 2022-06-30 | 20.18% |
| 2022-03-31 | 23.71% |
| 2021-12-31 | 23.40% |
| 2021-09-30 | 27.14% |
| 2021-06-30 | 24.82% |
| 2021-03-31 | 27.98% |
| 2020-12-31 | 29.75% |
| 2020-09-30 | 28.97% |
| 2020-06-30 | 20.36% |
| 2020-03-31 | 14.27% |
| 2019-12-31 | 23.10% |
| 2019-09-30 | 20.19% |
| 2019-06-30 | 19.87% |
| 2019-03-31 | 17.56% |
| 2018-12-31 | 16.37% |
| 2018-09-30 | 20.17% |
| 2018-06-30 | 19.91% |
| 2018-03-31 | 18.37% |
| 2017-12-31 | 17.67% |
| 2017-09-30 | 16.42% |
| 2017-06-30 | 19.81% |
| 2017-03-31 | 17.96% |
| 2016-12-31 | 18.22% |
| 2016-09-30 | 20.42% |
| 2016-06-30 | 25.34% |
| 2016-03-31 | 17.12% |
| 2015-12-31 | 16.93% |
| 2015-09-30 | 37.66% |
| 2015-06-30 | 19.53% |
| 2015-03-31 | 16.64% |
| 2014-12-31 | 17.84% |
| 2014-09-30 | 17.59% |
| 2014-06-30 | 18.03% |
| 2014-03-31 | 16.21% |
| 2013-12-31 | 19.48% |
| 2013-09-30 | 42.44% |
| 2013-06-30 | 19.85% |
| 2013-03-31 | 16.63% |
| 2012-12-31 | 18.96% |
| 2012-09-30 | 20.53% |
| 2012-06-30 | 21.32% |
| 2012-03-31 | 19.20% |
| 2011-12-31 | 21.12% |
| 2011-09-30 | 20.74% |
| 2011-06-30 | 20.47% |
| 2011-03-31 | 18.14% |
| 2010-12-31 | 19.61% |
| 2010-09-30 | 21.50% |
| 2010-06-30 | 22.88% |
| 2010-03-31 | 20.04% |
| 2009-12-31 | 21.29% |
| 2009-09-30 | 18.84% |
| 2009-06-30 | 22.32% |
| 2009-03-31 | 21.35% |
| 2008-12-31 | 21.26% |
| 2008-09-30 | 20.97% |
| 2008-06-30 | 20.43% |
| 2008-03-31 | 19.36% |
| 2007-12-31 | 21.50% |
| 2007-09-30 | 20.94% |
| 2007-06-30 | 19.94% |
| 2007-03-31 | 16.46% |
| 2006-12-31 | 21.20% |
| 2006-09-30 | 21.62% |
| 2006-06-30 | 19.70% |
| 2006-03-31 | 18.88% |
| 2005-12-31 | 19.58% |
| 2005-09-30 | 20.90% |
| 2005-06-30 | 22.08% |
| 2005-03-31 | 20.65% |
| 2004-12-31 | 21.28% |
| 2004-09-30 | 21.26% |
| 2004-06-30 | 21.03% |
| 2004-03-31 | 19.90% |
| 2003-12-31 | 19.63% |
| 2003-09-30 | 20.97% |
| 2003-06-30 | 21.06% |
| 2003-03-31 | 18.32% |
| 2002-12-31 | 17.41% |
| 2002-09-30 | 18.13% |
